Last reviewed · How we verify
23-PPV
23-PPV is a pneumococcal polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae.
23-PPV is a pneumococcal polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease in adults, Prevention of pneumococcal pneumonia and related infections.
At a glance
| Generic name | 23-PPV |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | Polysaccharide vaccine |
| Target | Streptococcus pneumoniae capsular polysaccharides (23 serotypes) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains purified capsular polysaccharides from 23 different pneumococcal serotypes conjugated or presented to elicit a humoral immune response. This generates protective antibodies that prevent invasive pneumococcal disease by promoting opsonization and complement-mediated killing of the bacteria. The vaccine is designed to provide broad serotype coverage for pneumococcal disease prevention.
Approved indications
- Prevention of invasive pneumococcal disease in adults
- Prevention of pneumococcal pneumonia and related infections
Common side effects
- Injection site pain or erythema
- Fever
- Myalgia
- Fatigue
Key clinical trials
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (PHASE3)
- Methotrexate in Retinal Detachment With Proliferative Vitreoretinopathy (NA)
- Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting (PHASE3)
- Compare PPV With and Without Silicone Oil in Managing Postoperative Endophthalmitis (NA)
- Intraocular Gas Tamponade for Treatment of Large Idiopathic Macular Holes (NA)
- Pressurized PPV 23GA Vitrectomy in Complicated Diabetic Tractional Retinal Detachment (PHASE3)
- Evaluation do Early Pars Plana Vitrectomy in Acute Endophthalmitis (NA)
- A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |